PAVmed Inc. is a highly-differentiated multi-product medical device company.  The Company's product pipeline includes NextFlo, a disposable infusion pump; PortIO, a long-term implantable vascular access device; Caldus, a disposable tissue ablation device; CarpX, a percutaneous device to treat carpal tunnel syndrome; and NextCath, a self-anchoring short-term catheter. In addition to its lead projects, PAVmed is working on projects which are currently in the conceptual phase. These additional projects cover a wide range of clinical conditions and procedures, including sleep apnea, extracorporeal membrane oxygenation, laparoscopic hernia repair, cardiac surgery, interventional cardiology and endotracheal intubation.

Type
Public
HQ
Queens, US
Founded
2014
Size (employees)
3 (est)+50%
Website
pavmed.com
PAVmed was founded in 2014 and is headquartered in Queens, US

PAVmed Office Locations

PAVmed has an office in Queens
Queens, US (HQ)
4600 251-1 Grand Central Parkway Service Road

PAVmed Data and Metrics

PAVmed Financial Metrics

USD

Net income (Q1, 2017)

(4.3 m)

EBIT (Q1, 2017)

(2.2 m)

Market capitalization (19-Sep-2017)

92.1 m

Closing share price (19-Sep-2017)

7.4

Cash (31-Mar-2017)

905.7 k
PAVmed's current market capitalization is $92.1 m.
USDFY, 2016

R&D expense

607 k

General and administrative expense

1.1 m

Operating expense total

1.7 m

Net Income

(5.7 m)
USDQ2, 2016Q3, 2016Q1, 2017

R&D expense

656.7 k

General and administrative expense

1.5 m

Operating expense total

2.2 m

EBIT

(2.2 m)
USDFY, 2016

Cash

585.7 k

Accounts Receivable

82.3 k

Inventories

155.5 k

Current Assets

741.2 k
USDQ2, 2016Q3, 2016Q1, 2017

Cash

3 m1.8 m905.7 k

Current Assets

3.1 m2 m1.1 m

Total Assets

3.2 m2 m1.1 m

Accounts Payable

216.1 k609.9 k934.2 k
USDFY, 2016

Net Income

(5.7 m)

Depreciation and Amortization

3.8 k

Inventories

(146.7 k)

Accounts Payable

877.6 k
USDQ2, 2016Q3, 2016Q1, 2017

Net Income

(1.3 m)(1.9 m)(4.3 m)

Accounts Payable

216.1 k609.9 k934.2 k
Y, 2017

Financial Leverage

-0.3 x
Show all financial metrics

PAVmed Market Value History

Traffic Overview of PAVmed

PAVmed Online and Social Media Presence

PAVmed News and Updates

BRIEF-Pavmed says successfully completes CarpX pre-clinical study

* Says completion of a pre-clinical human cadaver study, demonstrating that company's completely percutaneous carpx(tm) device reliably

PAVmed Company Life and Culture

You may also be interested in